Replay available

OneSource Specialty Pharma (NSE:ONESOURCE) Q2 2027 Earnings Call

OneSource Specialty Pharma (NSE:ONESOURCE) Q2 2027 earnings call, held 2026-10-27. Watch the replay and read the transcript on 6ix.

Tue, October 27, 2026 at 11:22 AMendedReplay
OneSource Specialty Pharma (NSE:ONESOURCE) Q2 2027 Earnings Call
Company
OneSource Specialty Pharma Limited (NSE:ONESOURCE)
Period
Q2 2027 earnings call
Date
Tue, Oct 27, 2026, 11:22 AM ET
Replay
Watch the replay on this page · 54 min

On 6ix: 6ix.com/event/onesource-specialty-pharma-limited-onesource-q2-2027-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Ladies and gentlemen, good day, and welcome to Q2 and FY 'twenty seven Earnings Conference Call of ONESOURCE Specialty Pharma Limited. As a reminder, all participant lines will be in the listen only mode, and there will be an opportunity for you to ask question after the presentation conclude. Please note that this conference is being recorded. I now hand the conference over to Mr. Abhishek Singhal. Thank you, and over to you, sir. Thank you, Dinesh, and thank you all for joining us today for the earnings conference call of Onesource Specialty Pharma Limited for the second quarter and half year ended September thirty two, twenty twenty six. We have with us Neeraj, CEO and MD and Anurag, CFO of the company, who will walk you through the key business and financial highlights for the quarter and for the first half of the financial year. I trust you have the opportunity to review our results release and the investor presentation, both of which are available on the company's website as well as on the stock exchange website.

1:01 The transcript for this call will be posted on the company's website within the next week. Please note that today's discussion will be contained forward looking statements, which should be viewed in the context of the risks inherent in our business. Should you have any further questions after this call, our Investor Relations team will be happy to assist you. I now hand over the call to Niraj for his opening remarks. Thank you, Abhishek, and a very warm welcome to everyone joining this late evening for our Q2 results. Q2 was a strong quarter for us. In fact, it was our third consecutive quarter of sequential growth and in line with the trajectory which we had outlined in our previous calls.

1:47 So if you saw that revenue increased 37% year on year, 15% sequentially. And in the quarter, we actually delivered more than 5,000,000,000 revenue. In fact, more hearteningly, EBITDA grew 53 year And And the second very fact half that of the pace of EBITDA the actually is was higher EBITDA growth was higher than the revenue growth, it really demonstrates the operating leverage, which is inherent in our business model. And in fact, if you look at the first half, it's put together both the quarters, it's been a 47% year on year growth of EBITDA.

2:44 So the growth both in this quarter as well as for the first half is actually being driven by the additional DDC capacity, which has come online in the last quarter, which is quarter two. And it helped us both commercial as well as MSA revenue coming in, thanks to that execution. And really staying with our DDC line expansion, many of you saw our second cartridge line is now running commercial batches. Even though the geopolitics actually impacted its start by almost six months, but the fact is that today, the line already since September, it is operational, And it has immediately doubled our total production sterile production days.

3:41 So the additional capacity, as we had said last time, the additional capacity really supports both the new launches which are coming in and provide us a significant ramp up of the commercial volumes, which we are expecting during the second half. I'm also happy to share with you that even our third line is has successfully completed its factory acceptance test in Germany and is now at our site as we speak, ready for qualification. I mean this line also the arrival was longer than anticipated, obviously, due to this extended transit times because of what's happening in The Gulf.

4:28 But as you also know that these are very bespoke lines, and I think I explained in my previous calls and interactions with many of you that these are lines built for much larger pad sizes. And therefore, they require quite rigorous qualification involving multiple European vendors. So keeping that in mind, while we are making every effort for it to start in Q4, but the commercialization might get pushed to the start of FY 'twenty eight. However, I just want to reiterate here that we'll have all three lines fully operational and available for FY 'twenty eight. And this is not just the filling capacity. I think that's what is important to highlight here and what really differentiates ONESOURCE from every other CDMO is that every one of our lines are backed by full end to end capabilities, whether it is not only cartridge filling, but assembly, labeling, packaging and so on, including cold chain, all under one group. And this differentiates us not only in India, but even globally.

5:43 Our semaglutide footprint continued to grow during the quarter. And our partner, Hikma, launched the first generic semaglutide in Saudi Arabia, which really expands our presence in a very important market, which is off patent. Also, more hearteningly, the Doctor. Reddy's API has thought has commenced, I think, which they also spoke about in their earnings call. And this would really help relaunch in Canada as well as launch across multiple other markets where they already have an approval. And apart from Doctor. Radhi's, also the supply ramp up from our other Canadian customers is also on track for the quarter three.

6:38 Now moving on to our second strong leg of our business, which is very emerging very fast, which is Biologics. It's increasingly becoming a very key growth pillar for us. And during the quarter, we had multiple new project wins, which is both from new customers who we onboarded as well as existing customers. And we have onboarded two projects from for end to end development to commercialization projects from a U. S. Biotech. We secured additional new program for one of our one of the top global animal health companies and our existing customer.

7:24 And this, as you know, came comes back to back up from the previous quarter where we had EU customer wins. Now these wins went whether The U. S. Or Europe, these really reflect the really integrated offering, which we have, which we call from gene to device in Biologics, which, again, very few CDMOs offer. And the fact that India's growing position as a trusted hub of global biologics biosimilar development as well as manufacturing. Now same is reflected in our biologics RFP funnel, which is at highest ever with multiple projects in advanced stages. And all this is really going to be driving the growth beyond FY 'twenty eight for us.

8:20 As far as our base business, especially the injectables, we discussed last quarter, we are adding new capabilities, including prefilled syringes and new lyophilization capacity. And the planned shutdown, which is of the site is, in fact, currently underway. It started at the back end of quarter two. But the new capacity will be available from next quarter onwards. And both at the same time, both our injectable and softgel business grew last quarter with multiple launches actually happening in several markets during the quarter. Another thing which we're always proud of, our compliance track record, where during the quarter, we successfully completed multiple regulatory and customer audits.

9:14 And also as the new capacity comes online, it's this track record is really maintaining the track record is really what the whole team is focused on. Just to conclude, with the Line two already commercial, Line three progressing, new launches coming through and coming more coming in the next coming quarters, a very strong biologics funnel and momentum across the business. We are already set for our next phase of growth. We expect second half to be stronger than the first. And basis that, we are also reaffirming our FY 'twenty eight outlook, which we have given of the $400,000,000 revenue and $160,000,000 EBITDA.

10:08 And also really important as we build the capabilities, capacities and the customer relationships, this, we believe, will really sustain the growth beyond the current year and beyond our guidance period. Finally, I really want to thank our teams for their commitment and our customers for the trust they continue to place in us. And I really want to thank everyone here and would be happy to take questions along with Anurag, our CFO. Dhanish, we're good to go. Can you please take the Q and A? Sure. Thank you so much, sir. Ladies and gentlemen, we will now begin with the question and answer session.

11:02 Participants are request to use handsets while asking a question. Ladies and gentlemen, we'll wait for a moment while the question queue assembles. Our first question comes from the line of Rupesh Tatia with Long Equity Partners. Please go ahead. Yes. Hi, sir. Am audible? Yes, Rupesh. Go ahead. Yeah. Congratulations, Neeraj, on fantastic set of results. First question is on capacity across all our businesses. So Softgel, what is the capacity utilization? Steriscience, I think we had a planned shutdown. So if you can, you know, quantify what what kind of revenue loss we saw in q two, and and is is that capacity going to be available in q three, or or it's gonna take a bit of time?

11:58 On DDC, is is it... Is the new line 500 liter batch size line, or are we still on the 200 liter batch size? And when when do we expect this capacity to reach optimum utilization line to BDC? So first question is on capacity across all of our businesses. Yes, Rupesh, thanks for asking. I think as we've been maintaining I'll start because I spoke about the DDC capacity. I'll answer that in that order. So the new line, which is there, we mentioned it last time also, is actually going to be increasing the output simply because it can work with a much larger batch sizes. So and this is the line which will run 500 liter batches for us.

12:48 And this is what is when we say doubling our trial capacity days, that's what we're really doing. So it's already the 500 liter batch size, which will happen on this line. In fact, all the new lines, which are getting added are able to handle significantly larger batch size. And that's why I mentioned with the increase with the because these are fairly bespoke lines, the qualification period takes much longer, and that's what you saw with the second line which come in. So it will all be 500 liters and even larger. In fact, these lines can handle even larger batches. As far as injectables, as I mentioned, the site where we took the shutdown, in fact, shutdown started only at the back end of the quarter ending September.

13:41 And it will the shutdown will last this current quarter. And then starting January, the lines will be available. These will add these will significantly increase our localization capacity and capability, which you know there is a big gap in supply and demand as far as localization capacity. And globally, In fact, most of the shortages, if you see in Europe or in U. S, if you see FDA's shortage list, 70%, 75% is contributed by injectables. And lyophilization is a big contributor to that. So we are looking at really improving that those supplies for these markets. And finally, on softgel, I think if we continue the traction continues. We have had multiple launches, which happened.

14:37 The capacity utilization continues increase. But you also remember, we have said that in our current site, there is no possibility for us to expand further. That's the reason we are going in for a greenfield site as far as sub gels are concerned, which would not only add significant new capacity, but also provide us opportunity to get into completely new area of containment and high potent softgels, which is, again, a demand a significant demand coming in from customers. So hope it answers. Yes. So just one clarification on second question I'll ask. So what is the capacity utilization in softgel? I mean, is it 60%, 70%? Or is it optimum? I mean, if if you can quantify it.

15:32 And this new line, I mean, it's a capacity 500 k... 500 liters, which is 2.5 x the existing line. So it will take quickly, quick quarters to go to optimization or we go to optimum utilization really fast. So those are the clarifications. And then the second question is, I mean, $400,000,000 revenue for FY '28. So q four exit run rate will will be, you know, let's say, $9,090,000,000, 38% or 36% margin will be be within striking distance of that as a Q4 exit run rate? Generally, we give this exit run rate across our company. So that is the second question. Yes, Rupesh. So as far as on the cartridge line, it's a fairly quick ramp up. There is because we have significant demand, as you're aware, both from existing customers, existing market and the markets which are opening.

16:34 So that the ramp up to optimum capacity is fairly quick as far the cartridge line is concerned. For softgel, it's because the there is a key requirement from customers who are moving from other the CDMO part who are moving from other manufacturing sites to us. So it takes a finite time. So it's ramping up. We started adding capacity last year, and we increased almost 3x that capacity. Now a significant part of it is already covered. And we already have a visibility of as I said, visibility of 80% plus from a capacity utilization point of view. That's why because we can't increase the capacity at this site, we are going in for a new greenfield.

17:32 As far as your the question on the FY 'twenty eight, as I said, right, we've reiterated our guidance for the full year, and we will have our lines, all three lines available for FY 'twenty eight. It is just the fact that because it's a Bisqo client, the qualification takes longer. So whether it will be available for full quarter four or part or not, that's something which I mentioned earlier. So to answer your question, FY 2028, line is available, and that's why we are retraining our guidance. Okay. Okay. Just one quickly, in biosimilar, will we be part of KEYTRUDA across our all our partnerships?

18:18 Because I think Fermicon is almost like a first to five is my understanding. So just if you can answer that question and then I'll get I understand. Back Of course, we Formicon is a key customer. But we I will not be able to talk on specific SKUs. Having said that, I can tell you that with all our customers, we have some of the largest products in the biosimilar space. Thank you. Our next question comes from the line of with ICIC Securities. Please go ahead.

19:11 Yeah. Hi, sir. Thank you for the opportunity. Sir, my first question is with regards to the supplies for doctor. So any indication you can provide us to, you know, how the ramp up is happening in terms of, you know, the revised APIs, what you would have got? And how are you looking forward for the next six months in terms of the capacity reservation for this client? Yes, Abdul, thank you for your question. So I think it is very much in line with what commentary they already made on their earnings call. The supply of API has, as I mentioned already, has already commenced. And by within this current ongoing quarter, we expect supplies to start.

20:04 Supplies to start first, obviously, to the Canadian market and then also multiple other markets where they already have approvals in emerging markets, India and multiple markets. And in fact, there are markets where the approvals are going to be coming in over the next two quarters. So we see that the numbers which they have given in their earnings commentary, we see those we don't see any reasons to not follow exactly those what they have said. Got it. So very helpful. And sir, I am referring to your presentation Slide nine, where you talk about six new order wins, which includes two biologic products.

20:54 So sir, you would help us understand what are those balance score about, whether it's in the DTC segment or apart from it also you're pursuing something? So these are when we talk about multiple wins, these are across. So there are the wins are in biologics, there are wins in DTC and there are wins in base business. That's how we actually operate and see. So it's across. So we as I mentioned earlier, the momentum is across our businesses. And the wins are both from a new launches perspective as well as existing. Sure. Sure. My next question is to Anurag, sir.

21:40 Sir, if I go through the cash flow statement, the trade receivables for the first half of fiscal 'twenty seven has gone up a bit. So anything to read about? Or it's just about the shipments, which would have happened towards the later part of the quarter? So thank you, Abdul. I want to actually give you the big macro picture. If you really look at the developments over the last couple of quarters in terms of the overall shipping lines and the lead times in terms of supply, getting the access the containers and everything. There is multiple impacts that we are seeing as a result of all this geopolitical development.

22:27 People that I talk to, people that I meet up, at least as a CFO community, I see everybody is experiencing about two to three percentage points impact on the P and L. When I look back in terms of comparing it to our results, I see that since most of our raw material is actually passed through, we don't have any significant impact, at least as far as the P and L is concerned. We've got implication on fuel, freight costs, shipping lines availability. But at least we've seen significant control as far as the P and L is concerned. But we do see some implication of these delays in terms of the overall cycle times when it comes to our working capital.

23:19 The delayed deliveries to the customer does impact at least forty five to sixty days in terms of the overall cycle time, I do believe that it is not structural, it is temporary. And it is only a timing impact. Hopefully, within a quarter or two, we should start seeing this getting normalized. Of course, there is implication as a result of the significant higher volumes in the last couple of quarters, which also shows up into the overall receivables. But clearly, there is no quality issue on the receivables. Thank you.

24:05 Our next question comes from the line of Girish Bhakaroo with OrbiMed. Please go ahead. Yes. Thanks for taking my question and congrats on great numbers. Miratil, can you comment on how many sterile days Line two was available in Q2? And how much did it run? So I think, like I mentioned that this was September was the month when we started the line getting active. But the fact remains that, as I said, on an annualized basis, it doubles our trial days. And that's what is, I think, the key metric you should be looking at. And thanks to this line, the ramp up of our not only the commercial sales, which we are going to do for Canada and other markets, but also gives us the ability to do MSAs, both for existing customers, which have been pending as well as add new customers, which also, as you know, we have not been able to do for last one year, thanks to the capacity constraint, which we had.

25:18 Now with this, immediately, we have got multiple options and multiple opportunities available to onboard customers and meet the demand of existing customers, especially when now Doctor. Adi is coming back on track. Understood. And in past, you have commented, I mean, of course, numbers from nineone, something around INR 60,000 per day. If I were to just, I mean, compare the batch size related factor, I mean, one should assume that this 60,000 will basically grow by 2.5x, right, by line two? It's like to like. So if I think if you look at the yield and so on, it's basically roughly 50,000 to 55,000 on the first line. And if it goes to 500,000, it is it comes to about anywhere between 120,000 to 130,000 because yield varies from product to product, from customer to customer. But yes, more or less, that's the math.

26:28 Understood. And I mean, of course, not really wanting the pricing number, but when we, let's say, look into FY twenty eight, can you give some broad comment on blended realization, which we can see? Will it stay largely same or reduce while the volumes will increase with the new line and more markets in the emerging markets, including Brazil, Turkey, all opening up. So how should we look at the realization? I think our realizations are there is not a major shift we are seeing in realization. As we've always said that our pricing to the customers has always been volume based and not market based, whether it's emerging markets or Canada or anywhere else.

27:15 And we don't see that changing. We have also said that the very fact that when there is a increase in batch sizes in a sterile business, the cost of manufacturing per unit comes down. And we are happy to share the savings there with our customers. So it's a fairly win win. The customers who are efficient enough and able to allow us to go to larger batch sizes, that efficiency benefit they get because we also get and we share that efficiency with them. Got it. And just last one, if I can squeeze. I know FY 'twenty eight is still forming up, but how much do you see can we forecast FY 'twenty eight guidance of INR 400,000,000?

28:11 Ballpark, is it 50 or much higher? I can only tell you that the very fact that I mentioned that our three lines, we are eagerly awaiting the third one to add and our so are our customers. So it will be DDC will be a strong contributor to our FY 'twenty eight. It will be like it will be a contributor to our second half. It will remain a very strong contributor to our FY 'twenty eight numbers. Our next question comes from the line of Chirag Shah with White Pine Investment Management Private Limited. Please go ahead.

29:03 Thank you for the opportunity and congrats for good set of results. Lilith, my first question is more on the batch sizes that you indicated. So if I have to break between line one and line two. Line one is we can assume with the optimal batch sizes, right, six days a week, etcetera. Line two where we would be? And how should we think about the flow through to EBITDA level because of that? Shyraq, thank you for your question. Although your question wasn't your voice wasn't very clear. But whatever I understood from you that your the earlier line, the first line had a max batch size, what we could do in that line was 200 liter, and that's that was what all our customers had moved to. Remember, we started on the same line at the 30 liters and ramped up to 200 liters.

30:06 On the new line, that's how basis demand. Currently, the capability of the line is to go up to seven fifty liters. But the customers right now are ramping up 500 liter. I think that's what the case is. And the very fact that there is very strong demand, which is there, both from existing customers, existing markets as well as new markets, which are going to be getting approvals, customers are going to be getting approvals and the new customers, which are coming on board. So there is, as I said, robust demand, and that's the reason we have said that we are also very excited with the fact that the third line is already at our site, where it's exciting development for us.

30:57 And the fact that I already mentioned, we have a very strong OpEx leverage in our business because the cost is more the incremental cost is very limited compared to the incremental revenue. And you will see that's how you already see the EBITDA margins improving for us quarter on quarter, again, thanks to the OpEx leverage. And that's the reason of us giving the guidance what we have given. Okay. Let me rephrase. I think you missed out my question. What I was trying to understand is in terms of efficiency level, in terms of number of batches that we run per week and obviously, the size of the batch, line one is at optimal level. Right? So efficiency gains coming from line one is limited operating.

31:49 Where are we in line two? You indicated that customers have gone up to 500, but not all customers would have been. Right? So the current results that we have, what element of, what do call, excessive costs are still lying, which and how should we think about it as you increase the revenue size from line two? See, so in terms of efficiency, yes, you're right that the Line one is running at optimal efficiency. Line two has given us the opportunity to do MSAs. So obviously, the utilization in MSA is different from utilization in commercial.

32:34 And it's going to be a ramp up, remember? It's as we start the market volumes are ramping up. And accordingly, our line will also be ramping up because there's a mix of MSA and CSA. A typical steady state picture is that in any line, it should be 75%, 25%, 75% commercial, 25% MSAs. And that's how we expect steady state for the second line also to be. Okay. And second, housekeeping questions for this. So one, what is this consumables that we see as a line item in raw material? Because it varies a lot to is it linked to any specific business or how... What exactly... What we classify is consumables?

33:26 And second, employee cost, there has been steady increase since last five, six quarters now. So are we still in hiring phase? How long we need to hire? When that will stabilize for us? Chirag, hi, Chirag. Thank you for those questions. Chirag consumables is a variable. It will depend upon the activity level. Every time we take a fresh batch, every time we take a engineering batch, every time there is a significant ramp up in volumes around any of those things, it will vary in those particular quarters. I mean those are clearly a function of the level of manufacturing activity.

34:15 And as we had said in the past, I mean, we are in line with our guidance in terms of ramping up our overall capability within the organization and building up the employee base in our Unit 2, which is our flagship site, which is ramping up capacity 2x to 3x within this year, clearly was a function of what we wanted to be. And we are on track with that. Clearly, there is nothing that surprises us in terms of the employee cost increase. The way you should look at our business is these are elements of fixed cost that we will have to enable the manufacturing lines with because these are specialized capabilities.

35:12 These are capabilities that require high level of quality observations. And for building all of that, it's a conscious focused effort towards building that capability and which we are working towards. Thank you. Our next question comes from the line of Harshal Patel with ASK Wealth Advisors. Please go ahead. Thank you, dear, and congratulations for a good set of numbers. So just one question to start with. The ETR, that's the expected tax rate. I believe you've got a lot of deferred tax also into it. So just wanted to know how should we look at this expected tax rate for 2728 going ahead and how long would the deferred tax benefit be available to us?

36:15 Sorry, I missed the name who asked the question. Very quickly, this is Anuradh. At this moment, we anticipate that you should assume through the current level of ETRs will continue through till FY 'twenty eight, at least till third quarter of FY 'twenty eight. Okay. So till the third quarter of FY 'twenty eight, sir, we should be assuming the current rate of taxation, is it that you said? That's right. Right. I mean these are these are of our brought forward losses, which we continue to utilize as we start as we continue to generate more profits. And these will continue to remain at least for a significant part of FY 'twenty eight.

37:03 Got it, sir. Just another second question on basically the capacities, I believe we've discussed it, but just one point to understand with respect to the new lines as well as the existing. So in general, to... As I understand it, this looks to be more as a, you know, a a strong demand and a supply constrained space. But when it comes to commissioning of new lines, ideally, how... What kind of a time frame does it take to, you know, scale up, let's say, from a 10%, 15% of a utilization to maybe 70%, 80% of a utilization level? So I think it's as I explained, these lines are not your typical lines. These are bespoke lines, which have been made to be able to deliver the kind of batch size output, which we which customers really require based on the robust demand, which we have.

38:08 I think what you need to understand, that's why because bespoke lines, having multiple vendors, these take the whole qualification process takes time, especially this the new line, which has come in, which has got a German isolator, a German filling line. So how because of that bespoke nature, the whole qualification time from the installation of the line to the start of commercial batches, it takes significant amount of time. But at the same time, the ramp up the good thing is once these lines start, the utilization is fairly quick. In fact, the current line, which second line, which we have started is, again, we are very quickly looking at a very, very significant utilization.

39:05 But remember, as a sterile process, which we have said, the overall utilization I'm talking about is staying in the range of two twenty five to two thirty days in a year. So because of all the work which it takes, media fails and the various quality reviews, which happen, That's why we've got two twenty five days. And we expect that the current line to be doing those two twenty five days fairly rapidly, considering the demand which we have fairly rapidly. Okay. Okay. And probably with the Line three that is slated to be on in probably Q4 or early days of FY 'twenty eight, I believe towards the first half of 'twenty eight, we should be expecting the same ramp up pattern for that as well, which is two twenty five to two thirty sterile days in a year?

40:00 That's correct. That's correct. Correct. Correct. Sir, just last two bookkeeping questions, if I may kind of squeeze in. I just also wanted to know for this Q2 results, do we have any impact of currency fluctuations on the margins or something like that? There is a marginal impact of currency fluctuation. It is reported in the financials called out So you will be able to see that in the publicly available financials that is it. It's about 300. Okay. Sir. Okay. So that was it from my side. If there's anything, I'll get into the follow-up.

40:49 Thank you. Thank you. Next question comes from the line of Mohammad Patel with Edelweiss Public Alternatives. Please go ahead. Can you hear me? Yes, we can. Yes, please go ahead. Yes. I have a question which is twofold. So one is how is Semaglutide doing in the markets in which our customers have got approval? And how are our customers doing currently? Yes. So Mohammed, I think as you have seen, right, that this was a product which was always constrained by supply rather than the demand, whether it is markets which are the largest in the world, like U. S.

41:47 And Europe, all these are the markets which are now available off patent, whether it is Canada, Brazil, India and many others. And I think the demand stays robust. I mean, the very, very clear visibility, which we have on numbers from India, if you see how from February, which was before the patent expiry of anywhere between 20,000, 25,000 units a month is now looking at more than 200,000 units a month as of September. And this is when typically, India takes for a chronic therapy like this, it takes three years to stabilize.

42:37 So if there is still a very strong growth path available there, We as we see in markets like Canada, which is obviously the largest market outside of U. S, we have seen already the market growing from 8,000,000 units to 12,000,000 units. And currently, genericization, today, it is more or less, we are talking about 16,000,000, 17,000,000 units and continues to grow. Again, because the generics have just launched in, unfortunately, Doctor. Atif had to come out of the market and now it will be back. So once everyone, all the players are sufficiently the product is sufficiently available, we will see that market to continue to grow. We have said earlier, and there's enough market analysis available that markets like Canada, markets like Brazil should be anywhere between four to 6x of what they are today. So which is so there is a very, very strong tailwinds behind this. And the fact that we have all the major customers in these markets, Canada, all for approvals with us, Brazil, many, many customers

44:09 waiting in the wings for approval, India, multiple approvals. So I think all this, the market movement is supporting the robust demand which we are seeing. So is it safe to say that FY 'twenty eight customer projections are strong at the moment? Yes. I mean, that's the reason the fact of our commitment of CapEx is based upon both what we see our customers giving robust demand as well as what we are seeing overall market demand going up. I have one last question. How should we think of Onesource growth beyond FY 'twenty? Yes. So I think I mentioned, the fact is that all our businesses, we have long legs beyond FY 'twenty eight. I'll start with drug device combination as the markets more markets open up.

45:14 You will see FY 'twenty eight, FY 'twenty nine, Europe starting to open FY 'thirty, 'thirty one. The big market, U. S. Will open Western Europe, U. S. So there is the DDC itself having very, very long legs. In emerging markets, you'll see growth already quite significant. So that's the reason that our capacity expansion had been kept in line with the fact that these products have got a number of markets opening up, large markets opening up. When it comes to our second pillar, which is Biologics, the guidance period, which we have given, all the revenue in the guidance period is coming from what we call MSA, which is a preapproval R and D revenue.

46:13 And post that is the time FY 'twenty nine onwards is when the commercial revenue starts. So in fact, those commercial revenues are of a very different order of magnitude than comparable small molecules. So very strong growth coming from biologics. Also the base business. So all the capacity which we are adding in our injectable business, which will be getting filled as over the next two to three year period. I mentioned soft gelatin, where that's completely new line coming up and a new modality of high potent softgels coming up.

46:58 I think that you will see all those contributing to the growth beyond FY 'twenty eight. High double digit is something that we expect? We have not given the guide as we progress, we will give you an outlook during FY 'twenty eight of what's going to be beyond that. Thank you. All the best. Thank you. Thank you. Our next question comes from the line of with ICIC Securities. Please go ahead. Yes, sir. Thank you for the follow-up.

47:45 So first one, I know Brazil, so I understand few generics have got an approval. But any color what we are getting from our customers as to when they are likely to launch this product there? Yes. So it's a very interesting market, Abdul, simply because it's, again, very high incidence of diabetes, obesity, a very, very strong focus on body positive and aesthetics and so on. So it's a very, very interesting market. Right now, while there are a couple of approvals, but there is only one generic, which is the local Brazilian company, which has actually launched the product. Many of our customers are waiting in the wings to get approval. And I think some of them have already announced publicly that over the next quarter or two, the approvals will come. And we are ready.

48:42 We are ready to support their demand. And you will see you will soon see approvals coming in. Understood. And sir, lastly, one bookkeeping question for the current quarter, that is Q2 of FY twenty seven, if you could share what was the MSA to CSA ratio for the BDC business? So it's it has started because the availability of the line, as I said, was from September onwards. So since then, we were able to do MSA. We are still because the new line had a very limited period, it will be difficult to give or it will not give you the correct picture. But as I said, in a steady state, we should be 75%, 25% between commercial and MSA revenues.

49:37 Got it. Thank you. Thank you. Our next question comes from the line of Sanjay with Ampersand. Please go ahead. Yes. Hi, sir. Thanks for the opportunity. Can you in addition to this EBITDA margin guidance, can you give something about your return on capital employed and deleveraging plans? Sanjay, hi. Clearly have a clear line of sight in terms of moving forward with our cash generation engine. We are currently in a significant investment cycle. And as we've said in the past, we will continuously move towards generating free cash going forward.

50:36 At this moment, we will continue to remain between 1.5x EBITDA margin in terms of our debt levels. We do anticipate that by end of FY 'twenty eight, we should be high 20s in terms of our ROCE returns. That's what we anticipate at this moment. We are clearly moving forward towards that goal. Thank you. Our next question comes from the line of Gaurav Bhamma with GM Financial. Please go ahead.

51:23 Sir, my question has been answered. Thank you for the opportunity and congratulations on the good side of numbers. Thank you. Thank you. Next question comes from the line of Prabhat Agrawal with Finmasters. Please go ahead. Thank you, sir. Just wanted to ask one question. You mentioned 12 launches this season. So how many are GLP-one DTC versus sterile injectable? So Prabhat, I think, as I mentioned, it's very significant launch, which we did was in Saudi Arabia by our customer, Hikma of semaglutide, which is very key.

52:14 And across the portfolio, the launches have happened in softgelatin, in injectables, in our markets like in U. S, in Europe, in some of the emerging markets. So it's a very large list. And obviously, we don't we can't talk about individual customers, only the ones which are in public domain or which are okay for us to be announcing. But I can tell you that this is across modalities, across markets and across customers. Thank you, sir. Sir, one more thing I wanted to ask. Why financial year twenty eight EBITDA is expected to $160,000,000 So is adjusted or reported?

53:07 No, it is. We have all our EBITDA numbers are reported numbers. Okay. Thank you, sir. Congratulations for the good setup number. Thank you very much. Thank you. Ladies and gentlemen, that was the last question for today. I now hand the conference over to the management for the closing remarks. Thank you and over to you, team. Thank you, everyone, for this late evening and really appreciate all the questions, and thank you for participating. Have a nice evening. Thank you so much, sir. Ladies and gentlemen, on behalf of ONESOURCE Specialty Pharma Limited, that concludes today's call. Thank you for joining us, and you may now disconnect your lines.

Follow OneSource Specialty Pharma Limited into a list and get an email when it puts out news.

Latest news releases

Companies on this call

More from OneSource Specialty Pharma Limited